We are live on ! Find out more
PIM

Partner Investment Management Portfolio holdings

AUM $13.9M
1-Year Est. Return 55.92%
This Fund
S&P 500
This Quarter Est. Return
+4.59%
1 Year Est. Return
+55.92%
3 Year Est. Return
+168.07%
5 Year Est. Return
+301.91%
10 Year Est. Return
–
AUM
$94.2M
AUM Growth
+$7.66M
Cap. Flow
+$4.36M
Cap. Flow %
4.62%
Top 10 Hldgs %
41.69%
Holding
106
New
19
Increased
31
Reduced
29
Closed
25

Top Buys

Rank Stock Value
1
AGN
Allergan plc
AGN
+$2.36M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$2.19M
3
BABA icon
Alibaba
BABA
+$1.84M
4
CRM icon
Salesforce
CRM
+$1.69M
5
DIS icon
Walt Disney
DIS
+$1.65M

Top Sells

Rank Stock Value
1
UNH icon
UnitedHealth
UNH
+$1.9M
2
NTGN
Neon Therapeutics, Inc. Common Stock
NTGN
+$1.43M
3
ARNA
Arena Pharmaceuticals Inc
ARNA
+$1.16M
4
AMZN icon
Amazon
AMZN
+$1.09M
5
LYV icon
Live Nation Entertainment
LYV
+$1.03M

Sector Composition

Rank Sector Weight
1 Healthcare 43.57%
2 Technology 14.03%
3 Communication Services 6.74%
4 Consumer Discretionary 5.25%
5 Financials 3.67%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NFLX icon
26
Netflix
NFLX
$307B
$1.22M 1.3%
33,310
+6,000
+22% +$216K
NYT icon
27
New York Times
NYT
$10.5B
$1.2M 1.28%
36,859
-15,448
-30% -$515K
TWLO icon
28
Twilio
TWLO
$29.3B
$1.18M 1.25%
8,644
+4,834
+127% +$644K
ALNA
29
DELISTED
Allena Pharmaceuticals
ALNA
$1.17M 1.24%
287,851
-9,110
-3% -$49.8K
SE icon
30
Sea Limited
SE
$68B
$1.14M 1.21%
34,270
+2,403
+8% +$65.1K
PFE icon
31
Pfizer
PFE
$149B
$1.14M 1.21%
27,670
-25,941
-48% -$1.03M
MOH icon
32
Molina Healthcare
MOH
$10B
$1.09M 1.16%
7,617
+286
+4% +$39.2K
TCOM icon
33
Trip.com Group
TCOM
$29.1B
$1.07M 1.13%
28,959
+16,960
+141% +$669K
ARNA
34
DELISTED
Arena Pharmaceuticals Inc
ARNA
$1.06M 1.13%
18,159
-22,446
-55% -$1.16M
XYZ
35
Block Inc
XYZ
$47B
$1.05M 1.11%
14,459
-3,182
-18% -$222K
SRPT icon
36
Sarepta Therapeutics
SRPT
$1.77B
$1.02M 1.09%
+6,730
New +$818K
BOLD
37
DELISTED
Audentes Therapeutics, Inc
BOLD
$987K 1.05%
26,063
+9,240
+55% +$355K
PFE icon
38
CALL
Pfizer
PFE
$149B
$983K 1.04%
+23,926
New +$950K
ELV icon
39
Elevance Health
ELV
$84.9B
$980K 1.04%
3,473
-3,455
-50% -$944K
MSGS icon
40
Madison Square Garden
MSGS
$9.43B
$893K 0.95%
4,474
-527
-11% -$112K
DXCM icon
41
DexCom
DXCM
$31.3B
$872K 0.93%
+23,272
New +$732K
MYOK
42
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$866K 0.92%
17,272
+1,910
+12% +$93K
TMO icon
43
Thermo Fisher Scientific
TMO
$214B
$865K 0.92%
2,947
-2,683
-48% -$739K
NVRO
44
DELISTED
NEVRO CORP.
NVRO
$745K 0.79%
11,489
+2,297
+25% +$143K
ESPR
45
DELISTED
Esperion Therapeutics
ESPR
$731K 0.78%
15,722
-3,125
-17% -$147K
COUP
46
DELISTED
Coupa Software Incorporated
COUP
$661K 0.7%
5,217
-194
-4% -$20.8K
ALGN icon
47
Align Technology
ALGN
$12.1B
$636K 0.68%
2,325
-1,029
-31% -$311K
IRTC icon
48
iRhythm Holdings
IRTC
$4.21B
$607K 0.64%
7,672
+2,107
+38% +$153K
EXAS
49
DELISTED
Exact Sciences
EXAS
$592K 0.63%
5,014
-2,101
-30% -$212K
OEF icon
50
PUT
iShares S&P 100 ETF
OEF
$20.5B
$575K 0.61%
+13,400
New +$1.71M
1
2
3 4 5

Similar funds

SWM
Sequoia Wealth Management Hoffman Estates, Illinois $12.9M AUM 25.75% 1-Year Est. Return
ACM
ADI Capital Management New York $17.5M AUM 49.32% 1-Year Est. Return
ECAU
Everett Capital Advisors (UK) London, United Kingdom $18.6M AUM 22.81% 1-Year Est. Return
SL
Signition LP New York $20M AUM 28.26% 1-Year Est. Return
DII
Domini Impact Investments New York $7.59M AUM 47.68% 1-Year Est. Return
FIM
FourPoints Investment Managers Paris, France $21.1M AUM 11.11% 1-Year Est. Return
EM
Emancipation Management New York $22.4M AUM 18.33% 1-Year Est. Return
BHC
Balch Hill Capital San Francisco, California $22.8M AUM

Partner Investment Management's Q2 2019 Portfolio in Review

As of Q2 2019, Partner Investment Management held 106 positions worth $94.2M, up 8.9% from $86.5M the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Partner Investment Management deployed $4.36M of net new capital in Q2 2019, opening 19 new positions and adding to 31 existing holdings. Its largest new stake was BioMarin Pharmaceuticals: 25,610 shares worth $2.19M.

By sector, the portfolio is most concentrated in Healthcare at 44% of assets, down from 46% a quarter earlier, followed by Technology and Communication Services.

On the sell side, the largest reduction was UnitedHealth, an estimated $1.9M trimmed.

  • Partner Investment Management's largest Q2 2019 buy was BioMarin Pharmaceuticals: 25,610 shares worth $2.19M.
  • Partner Investment Management added most to Allergan plc in Q2 2019, an estimated $2.36M increase.
  • Partner Investment Management's biggest Q2 2019 reduction was UnitedHealth, cutting an estimated $1.9M.
  • Partner Investment Management fully exited Amazon in Q2 2019, selling an estimated $1.09M.
  • Partner Investment Management's ten largest holdings make up 42% of its $94.2M portfolio in Q2 2019.
  • Partner Investment Management opened 19 new positions and closed 25 in Q2 2019.
  • Partner Investment Management's portfolio value rose 8.9% quarter-over-quarter to $94.2M.

Based on Partner Investment Management's 13F filing for Q2 2019, filed 14 Aug 2019.